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 EXECUTIVE SUMMARY 
According to recent analyst reports, merger / acquisition (M&A) and technology licensing 
activity in the pharmaceutical industry is not going to see any slow downs in the next few 
years (The Boston Globe, 2008). With patents of high revenue drugs expiring, risk of 
development increasing and changes in the global landscape,  M&A and licensing remain 
key strategies that companies use to improve their competitive position in the industry. 
Managing these processes is incredibly resource intensive for companies. Understanding 
competition, locating partners, and maintaining ongoing communication is resource intensive 
and there remains an unmet need to improve services for organizations embarking on this 
aspect of business development.   
 
 Web 2.0 is a term used to describe web sites that have a specific set of competences 
and provide a platform where users can interact with the site and with each other. Most of us 
are familiar with successful Web 2.0 sites, like Google, Facebook and YouTube. These sites 
have an unmatched ability to exponentially rise in value and the entrepreneurs that have 
pursued these types of service platforms have produced immense returns for themselves and 
their investors.  
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  We propose the creation of Pharma 2.0. A company that provides a free web portal 
and online service centre for pharmaceutical and biotechnology partnering and 
communication. Our team has a combined experience of over 25 years in the areas of 
intellectual property (IP) and contracts law, mergers, acquisitions, licensing and operations. 
This experience has indicated that an unmet need remains. Companies expend high amounts 
of resources to carry out the processes involved in understanding their competitive landscape, 
finding partners, communicating and completing deals. Our service will provide 
organizations with a user-friendly web site where all of their partnering needs can be met. 
 
 The anticipated start up financing is $500,000. This funding is expected to be 
received through grants and other personal investment. In year 2 we will seek an additional 
$1.0 million investment funding to continue to expand operations. We will offer investors 
30% of the firm, an amount above the actual 23% value. 
 
 Our exit strategy is by acquisition. Year 3 valuation has been calculated at $5.3 
million using an industry EBIT multiple of 6. While the multiple is high (due to Web 2.0 
industry values), this estimate is still considered to be conservative as revenue estimations 
were kept below industry forecasts (as per benchmark organizations). The values provide 
investors with an IRR of 26.5% (Appendix 2). While we feel this value is sufficient, we may 
extend the exit time to Year 5 in order to achieve a higher value and higher ROI.  
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 1:  BUSINESS OVERVIEW 
Pharma 2.0 is a service company consisting of a web portal and additional services that offer 
a peer-to-peer networking environment for corporations, universities, and research facilities 
to locate, coordinate and collaborate on various projects without the necessity of extensive 
resources. This business venture will combine the power of an unlimited, advertising-based 
Web 2.0 application with the dynamic world of pharmaceutical (pharma) and biotechnology 
(biotech) drug development. 
 
Pharma 2.0 is; 
• Part of the 650 billion dollar global pharmaceutical / biotechnology industry; 
 
• A professional web portal with clear networks and search features to provide 
companies with everything they need to gain a competitive advantage in the 
industry in one place, with no cost; 
 
• A site for breaking industry news through: news feeds, RSS feeds, white papers, 
seminars; 
 
• A link to the best global conferences in the industry; 
 
• Run by a management team with strong pharmaceutical/biotech legal and 
business backgrounds. A combined experience of over 25 years in 
mergers/acquisitions business and intellectual property law - invested in 
assisting corporations to make the best use of the resources invested in 
partnering activities; 
 
• A place where advertisers can get a solid return on investment and access to 
valuable customer information; 
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 • Strategic, operational and legal consulting in regard to patent protection, 
mergers, acquisitions and licensing;   
 
• Secure online data rooms for the exchange of confidential information packages. 
 
Corporations are embracing new business models in an effort to combine traditional 
methods with open innovation and collaboration (Tapscott, 2008). For the pharmaceutical 
industry this is not only a novelty but, in recent years, has become a necessity. Due to the 
high risk of failure in drug development, companies survive by keeping their technology 
pipelines well stocked to increase the probability of moving drugs beyond research and 
development to commercialization. In the past, pharmaceutical companies possessed the 
internal resources and capabilities to develop their own pipeline technology. However, in the 
last decade, changes in the FDA and other global regulatory institutions have made it 
increasingly difficult for drugs to reach late stage development. Large pharma and biotech 
companies are now heavily reliant on partnerships to gain access to novel technology, while 
small to mid size biotech and start-up organizations rely on passing technology along or on 
financing from a partner to continue their development. Without collaboration, the industry 
would not continue to foster many of the medications available on the market today. Between 
2004 and 2006, the value of pharmaceutical and biotech deals tripled from US$30 billion to 
US$90 billion. Clearly this is an industry where alliances are becoming increasingly more 
important.  
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 We have been in this industry for a combined 25+ years and feel that there is an 
unmet need for viable methods of locating and communicating with potential partner 
organizations. There are limited means by which companies can communicate with each 
other and those that do exist are highly priced and not readily available to start-up or small 
organizations. Some methods of searching for partners are: Internet databases (can be over 
$100,000/year), partnering conferences, consulting companies, investment banks, and 
personal searches. Most of these options require significant investment from companies. For 
example, partnering conferences, can cost a company up to $10,000 per employee 
(depending on location) and consist of series of brief thirty minute meetings between 
organizations. This is not only exhausting, but often result in few significant leads. Many 
small biotech and start-up companies can’t afford to waste critical resources on attending 
these conferences when they are trying to advance their scientific research, and consequently, 
good technology may be passed over due to the lack of affordable communication. 
 
Our company will provide an Internet service for organizations to promote 
themselves through online profiles, networking opportunities, and updated industry 
information. Access and registration on the site will be free for those wishing to pursue 
partnerships, as we will seek sustainable revenue via a traditional advertising model. The site 
will remain highly professional both in its visual layout and content, and advertising will be 
restricted and sorted by industry related goods and services (e.g. Contract Research 
Organizations, IP Firms, Trade Magazines, etc.). 
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 Various services will also be offered by Pharma 2.0. These will consist of consulting 
for legal and business services, specializing in intellectual property law, mergers/acquisitions 
and licensing. These services will be made available to companies both on and off the web 
site and will be structured as a fee for service. Other future add-ons to the site will include 
secure due diligence areas (where clients can exchange protected information), financial 
consulting, and arbitration/mediation services. With our combined education and experience 
in the pharmaceutical industry, we are confident that we have a good understanding of client 
needs in these matters and are capable of providing the competitive edge necessary to bring 
this service to the market successfully. 
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 2:  INDUSTRY 
 
Pharma 2.0 spans two business environments. The first is the pharmaceutical / biotech 
industry, the second is the Web 2.0 or online peer-to-peer networking environment. 
 
2.1 Pharmaceutical / Biotechnology Industry 
 
The pharmaceutical industry is one of the largest and most profitable industries in the World, 
with annual sales expected to reach between $735 and $745 billion in 2008 (Arnum, 2007). 
In 2006, Fortune magazine listed Pharmaceuticals as being the #5 industry ranked for most 
profitable businesses, but growth is slowing. The 2008 growth forecast is 5 – 6%, down from 
the 6 - 7% in 2007 and in some of the major markets it is expected to be even lower at 4%  
(Arnum, 2007). There are several reasons for this declining rate. One is that companies’ 
revenue streams are under pressure due to patent expirations and weak pipelines; Another is 
that the cost and risk of developing drugs has risen; And finally, there has been increasing 
globalization in R&D with many developing countries establishing their own labs and 
manufacturing facilities (Regent Atlantic Capital. LLC, 2007). One of the ways companies 
are dealing with these threats is by implementing new business models that  rely more 
heavily on outsourcing and open innovation. Traditionally pharma companies did not rely on 
external resources for technology or for research operations. Everything was vertically 
integrated. Now, however, companies are minimizing risk by seeking external sources of 
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 intellectual property, new pipeline products, R&D and manufacturing operations. 
Partnerships are growing increasingly more important as a strategy and in today’s 
competitive environment, many companies would not survive or grow without them 
(PharmaVentures, 2005). 
 
In 2003, the cost of moving a drug through development to commercialization had 
reached an astounding estimation of $802 million USD (DiMasi, Hansen and Grabowski,  
2003). For the majority of companies, this is far too much of a burden to take on in its 
entirety. The increase in the time it takes a company to get a drug to market is drastic. Figure 
1 shows the founding dates of various organizations and the trend of increasing time to 
market for drugs.  
 
      
Company Founded First product 
launched
Years to 
Launch
Genentech 1976 1982 6
Biogen Idec 1978 1986 8
Amgen 1980 1989 9
Genzyme 1981 1991 10
Gilead Sciences 1987 1996 9
Cephalon 1987 1998 11
Celgene 1986 1998 12
Sepracor 1984 1999 15
ImClone Systems 1984 2004 20
Amylin Pharma 1987 2005 18  
Figure 1 - Number of Years to Product Launch 
 
(created by M. Seltenrich, data from Sarazen and Hillenbach, 2008) 
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 Figure 2 illustrates the lengthy process of development, and at which points various 
organizations may come into play (McCully, 2008). 
 
Figure 2 - Drug development process & organizations involved 
 
         (created by M. Seltenrich, with data from McCully, 2008) 
Most drugs begin in a discovery phase which takes place at a university, other 
institute, or within some biotechs. This phase is research oriented and is about understanding, 
or “modelling” the disease and identifying various targets (proteins, receptors, etc.) within 
the human body. Once an understanding is established, drug candidates are produced and are 
screened in vitro . Screening will determine activity and affinity for the target. Early testing 
refers to preclinical and toxicology studies. These are typically done in animals and are used 
1
                                                 
1 Testing done in cell cultures and not in human or animal subjects 
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 to determine whether the drug has efficacy in the appropriate disease state, and whether it is 
safe to test in humans. This can be a prolonged stage of development as many different drug 
candidates enter into preclinical studies, only to fail due to lack of sufficient activity or 
affinity, or due to adverse events in the animal models.  If a compound proves to be safe, and 
is selected during preclinical development, then it will enter into a Phase I clinical (human) 
trial. During this trial, the drug will be tested in a small population (10s to maybe 100s of 
individuals). Often this phase is divided into sections referred to as “a” and “b”. These early 
clinical trials test for efficacy and toxicology in humans. Following this stage,  the company 
developing the compound must submit an Investigational New Drug (IND) application to the 
American Food and Drug Association (FDA) for approval to continue moving the drug 
through further clinical studies and into larger populations. Often, what occurs at this point is 
a significant diligence process by the FDA of the company’s scientific rigor. The FDA must 
ensure that all aspects of development are carried out correctly in order to prevent harmful 
substances from reaching the market. They will commonly send back a request that further 
studies be completed if an area needs more development to rule out harmful effects. Once the 
IND is approved, the drug will be qualified to move into advanced clinical studies: Phase II 
and Phase III.  Unlike Phase I, Phases II and III are lengthy and require an enormous amount 
of resources. They involve larger populations (up to several thousand individuals), and often 
occur in multiple centres (DiMasi, Hansen and Grabowski, 2003) over several years. 
Following successful clinical trials, the company managing the development can choose to 
launch the product, thus maintaining the marketing rights and responsibilities, or can choose 
to license it for commercialization. Many choose the latter as they are not equipped with the 
sales or marketing teams to go commercial. 
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 With increasing complexity in technology and understanding of the human body (e.g. 
gene mapping), companies are investigating more complicated areas of drug development. 
With this comes a significant pressure to obtain data and prove safety. Partnerships are one of 
the most common routes to getting a drug commercialized as they enable companies to 
access the resources needed to successfully complete development. Figure 3 shows the trend 
in total deals (including mergers, acquisitions, and licensing) for products both into and out 
of the organizations between 1997 and 2004.   
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Figure 3 - Total deal trend 1997 to 2008 
 
          (created by M. Seltenrich, with data from McCully, 2008) 
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  The trend of the graph shows that partnerships have been steadily increasing in the 
last decade.  Recap2 and other market intelligence resources continue to note and comment on 
this trend as organizations move toward a more open operational structure. This structure has 
become particularly apparent among the large pharmaceutical companies that are now 
steadily in-licensing a stream of technology from the smaller biotechnology (biotech) 
research and development (R&D) organizations.  Figure 4 shows the number of biotech out-
licensing deals that occurred between 2001 and 2006. While remaining fairly steady up until 
2003, the increase of pharmaceutical companies drawing from biotechs becomes more 
apparent in the years between  2004 and 2006 (Recap, 2007). 
 
Biotech Out-Licensing Deals 2001- 2006
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Figure 4 - Biotech out-licensing deals 2001 to 2006 
 
         (created by M. Seltenrich, with data from McCully, 2008) 
                                                 
2 Recombinant Capital (Recap) is a San Francisco Bay Area-based consulting firm specializing in biotechnology alliances, earned alliance 
revenues, product sales, employment agreements, company information and capitalization. 
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 Merger and acquisition (M&A) activity among organizations is also proving to be on 
the increase. Unlike licensing a specific technology, these types of deals can fulfil several 
needs of an organization. By acquiring companies, they can gain access to new technology, 
as well as the key individuals responsible for generating the data. For small and medium 
enterprises, M&A often generates news for an organization which may help to boost its stock 
price, or promote funding opportunities. Finally these types of deals can provide a company 
with various locations or facilities necessary to grow. 
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Figure 5 - Mergers and acquisitions 2001 to 2007 
(created by M. Seltenrich, with data from McCully, 2008) 
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 Figure 5 shows the number of M&A deals between pharma and biotech companies 
and between biotech companies. The trend of biotech to biotech seems to be mainly stable 
over the past seven years, while there has been an increase in the number of deals taking 
place between biotech companies and pharma companies. This is, again, due to large 
companies that previously maintained in-house R&D transitioning to the open model and 
bringing in technology from outside sources. The trend is currently believed to be moving 
toward the concept of the biotech companies acting as technology “factories” for large 
pharmaceutical companies (Kendall, 2008).  
 
For a company seeking partnerships, finding the right opportunity  requires a 
significant effort. Market intelligence resources claim that approximately 37% of all pursued 
deals are successful. Recap lists that there are currently 2,866 biotech and pharmaceutical 
companies globally. All of the companies listed in the Recap database have engaged in 
partnering activities at some time. While this does not represent the entire market (many of 
the smaller companies are not included), it does provide some indication of the number of 
companies that are involved in developing drugs at some stage, and would potentially be 
seeking collaborations.  By this estimate, if approximately 600 deals were successful in 2005 
(as per Figure 4), then roughly 1621 deals were attempted, and many more companies likely 
went through the process of searching for potential collaborations. The type of partnership 
sought, depends on the size and capabilities of the organization. For example, it may be a 
start-up company that is licensing technology from a university in order to gain access to the 
intellectual property and to continue development, or it may be a large pharmaceutical 
company that has shelved a compound (no longer developing it) and is out-licensing it to a 
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 smaller biotech for research. More commonly, it is a small or young biotech company that 
does not have the financial capability, or infrastructure to complete later stage studies. These 
companies need to partner with a larger biotech, or pharmaceutical company to continue 
work and complete IND3 enabling studies. The latest these organizations would partner is 
likely at the end of Phase II clinical studies, as most cannot afford to complete a Phase III.  
 
Performing an effective partner search typically begins internally with a meeting of 
appropriate staff members (e.g. senior management, corporate development and scientific 
teams), during which a decision is made to commence a merger/acquisition or an in/out 
licensing search. Criteria are developed to fit the organization’s needs, and several methods 
are then chosen for the search. Searching is typically managed by the business development 
team with frequent reports to senior management. The science team may be brought in to 
evaluate technology or answer technical questions but are not usually involved in the search 
or the developing relationship, unless they come by this through their own scientific network.  
 
The most cost effective way for business development executives to search for 
potential partners is via the internet or through previous contacts, combined with cold calling. 
This is a difficult way to explore opportunities, as it can take a significant amount of time and 
render few plausible results. The team is much better off attending the many annual 
partnering conferences where they have the opportunity to present to a variety of previously 
chosen companies, as well as engage in social networking. Partnering conferences can cost 
                                                 
3 IND = Investigational New Drug ;  A standard document that must be approved by the FDA before a compound can enter into human 
clinical trials (Phase I, Phase II, Phase III, possibly Phase IV) and then to market.   
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 up to $3500 per attendee in registration fees alone, and take place in a variety of locations. 
This creates added expenses of travel and accommodation. However, the most important way 
for a company to partner depends on conferences and networking, and therefore, an 
organization must budget to send employees. An average company would want to attend 4 or 
more conferences per year to generate leads. The budget for this would be approximately 
$5000 per delegate per conference. A small biotech company would have to budget at least 
$20,000 per year for an employee to attend. Most companies will send 2 or more delegates, 
which requires a budget of between $40,000 and $80,000 per year to network and establish 
communications. If these searches do not provide relevant results, a consulting company or 
investment bank may be brought in to assist in identify and screen appropriate partners. The 
activities related to seeking out potential partner companies can be completed in any order 
depending on the company’s resources and preferences. 
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 2.2 Web 2.0 – Online Environment 
 
The World Wide Web has become one of the most effective ways to communicate 
information rapidly to a large market. In the late 1990s, changes began to take place in the 
technology and architecture of web sites. These changes created a unique style that allowed 
users to participate and interact with the web and each other like never before. Today, the 
sites have developed into an unparalleled influence as the next generation of online 
platforms. 
 
The phenomenon was branded during a brainstorming session between O’Reilly 
Media and MediaLive International (O’Reilly, 2005). The two groups were discussing ways 
to accurately describe the changes occurring in site development and how these were 
contributing to internet use. They chose the name Web 2.0 to indicate the advancement of the 
original Web to another level, much like the use of numbered versions in software upgrades. 
Web 1.0 is now considered to be the original information network (Internet), made up of a 
platform of web sites that hyperlink to each other to create a global collection of information 
available to anyone with access. Web 2.0, on the other hand, can be described as the 
compilation of dynamic, social networking and service applications that are changing the 
way individuals express themselves, communicate and do business online (Shuen, 2008). 
Still, a true definition of the term “Web 2.0” has been difficult to establish and Tim O’Reilly 
has chosen to describe it through a set of competencies. The below list is taken directly from 
the paper “What is Web 2.0” written by O’Reilly in an effort to address the aspects of these 
sites and appropriately describe the concept. 
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 Web 2.0 Competencies: 
• Services (not packaged software) with cost-effective scalability 
• Data sources that get richer as more people use them (i.e. network effects) 
• Trusting users as co-developers 
• Harnessing collective intelligence 
• Leveraging the long-tail through customer self-service 
• Software above the level of a single device 
• Lightweight user interfaces, development models, and business models 
  
Although many people remain unfamiliar with the term, most are currently 
contributing to its business model (Shuen, 2008). Examples of commonly used 2.0 platforms 
include Google, Yahoo, YouTube, Flickr, and Wikipedia. Each of these sites demonstrate a 
unique competency for being an online source of collective harnessed data and intelligence 
created by multiple users and which becomes more valuable with an increasing network. This 
increasing, positive value that is created as more users adopt a technology is referred to as the 
“network effect” (Shuen, 2008).  
 
Network effects are the main force that drives the success of 2.0 applications and 
creates the barrier to entry in competition. A traditional example of a network effect is the 
adoption of the telephone or fax machine. With one user, the value of the technology is 
literally zero, since you cannot phone or fax another user. However, as more and more users 
adopt the technology, the value exponentially increases. This rate of adoption follows an S-
curve, as shown in Figure 6.  
 25
  
               
 
Figure 6 - Adoption curves of Interactive and Non-Interactive Innovations 
(created by M. Seltenrich, adapted from Mauboussin, 2004) 
 
The two S-curves represent the adoption rates of two types of technologies. The solid 
line represents technologies that are non-interactive, such as videocassette tapes or game 
consoles. The S-curve develops due to associated costs and complimentary products. For 
example, if you owned a Beta machine, you would very quickly find it difficult to rent tapes 
that it could play and so the adoption of the VHS tapes would increase rapidly once a certain 
point was reached. This point is called the “tipping point” and it is the place on the curve 
where the amount of users has reached the critical mass necessary to cause the rate to 
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 increase rapidly. The dashed line represents the curve that forms from an interactive 
technology, such as E-bay. The S-curve is steeper and the tipping point occurs in less time 
than that of a non-interactive technology. This is because in an interactive technology, late 
and early adopters can influence each other. In other words, the benefits from each new user 
are passed to all existing users and all future users (Mauboussin, 2004). The point of critical 
mass in an interactive technology is considered to be between 5 and 20% of the market. It is 
at this point that technology adoption increases at an increasing rate, regardless of whether 
the originator continues to promote it (Mauboussin, 2004). 
 
Once a critical mass is reached, the network effect will drive the increase in users on 
its own. Eventually network users become locked-in and switching costs increase, creating a 
competitive advantage and barrier to entry. The switching costs associated with a free site are 
not linked to monetary value as they are for traditional products. They are brand-specific 
training and search costs (Mauboussin, 2004).  Once a user is familiar with a technology, 
there is a cost associated with having to learn a new one. This costs time and productivity and 
users will be hesitant to switch to something they’re not comfortable with. Search costs are 
incurred when buyers and sellers (in this case, partners) attempt to locate and communicate 
with each other. The cost here is to locate and learn about alternatives (Mauboussin, 2004) 
that can offer the same benefit. 
 
The immense value that can be created by a successful 2.0 web site is evident when 
reviewing some of the recent financial transactions that have taken place in the last two 
years. In the Fall of 2006, Google purchased the online video site YouTube, for $1.65 billion 
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 (Monica, CNN Money, 2006). A year later, the powerhouse Microsoft bought a small 1.6% 
stake in Facebook for  $240 million (Stone, NY Times, 2007). And in early 2008, Microsoft 
again surfaced with a $44.6 billion offer to purchase the search engine Yahoo (Whoriskey, 
Washington Post, 2008). Yahoo declined this offer with a statement that it was ‘inadequate’ 
(BBC News). 
 
Web 2.0 business applications create a space where the average person can participate 
in the economy like never before (Tapscott & Williams, 2008). The accessibility of 
information allows people to share knowledge, add value and effect decision making on a 
much larger scale (Tapscott & Williams, 2008), and many companies are exploring this 
wealth of collaborative knowledge. In a survey by the Economist Intelligence Unit, key 
findings showed that companies are confident Web 2.0 applications will deliver business 
benefits in the near future, and it isn’t taking long for some of the top executives to realize 
the potential. Web 2.0 is spreading like wildfire across industries, as savvy top executives in 
all areas begin to realize its immense benefits. Examples of companies that have had success 
with Web 2.0 are: Cisco, Procter & Gamble, IBM, Wells Fargo, Boeing, FedEx , Morgan 
Stanley and Pfizer, just to name a few. Many more are taking the leap to incorporate a 2.0 
model into their enterprise (Tapscott, 2008). 
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 3:  PRODUCTS & SERVICES 
 
At the centre of most successful high tech companies are products and/or services that truly 
meet the needs of the market (Viardot, 2004). The operational level of product development 
is the first step in evaluating these needs and creating a suitable match. Product development 
can be looked at from three levels. The first level is the essence of the product, or how well it 
matches consumers’ needs; the second is the product’s physical attributes; and the third is the 
shell or the additional services offered  (Viardot, 2004). Each of these levels must be 
carefully considered and developed appropriately for the market if the product is to have 
success.  
 
3.1 Pharma 2.0 Networking Portal 
 
Pharma 2.0 provides a business to business networking web portal for the pharma / biotech 
industry. The purpose of the site is to provide industry professionals with a free space where 
they can promote their company, learn about the competitive environment, interact with 
colleagues, build a network and engage in the steps toward developing collaborations. 
 
The Essence  
Pharma 2.0 was conceptualized as the result of our combined experience in the business 
development and legal aspects of the pharma / biotech industry. Dealings in these areas led to 
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 the realization that partnerships are absolutely critical in the industry and that even though 
they are growing, there is still a gap in the area of communication. Small and medium 
enterprises invest such a high amount of resources into development of their products, that 
they have very little left to devote to finding partners. At the same time, if they lack resources 
they’ll be limited in how far they can take a drug through development, and will inevitably 
require a larger company to provide funding or to license the drug at some point. Thus, the 
product was envisioned to fill this need by providing a web portal, available at no cost, for 
companies wishing to promote themselves and their products. To provide this service, the 
site will use pay-per-click advertisements as a means of generating revenue. The product is 
intended to provide a networking space where users can create innovative and meaningful 
business relationships within the pharmaceutical industry, thereby significantly improving 
the strategic risk involved in drug development. 
 
The Physical 
Pharma 2.0 will be a web portal that combines a professional online environment with a 
standardized format in order to optimize the ease of use and the flow of information. Web 2.0 
is on the periphery of mainstream business-to-business applications, particularly within the 
pharmaceutical industry, and it is anticipated that industry professionals may be slow 
adopters of a free and open system. To raise the network to a critical tipping point, a clean 
and standard architecture is essential as well as “Web 2.0: A strategy Guide” (Shuen, 2008) 
offers basic ways that a 2.0 site can build in these features.  
 
 30
 One of the most fundamental aspects of positioning the product is naming it. Consumers 
can’t purchase what they don’t know (Moore, 1991). We have purposely chosen the name 
“Pharma 2.0” because it is a simple yet powerful name that combines the industry with the 
concept. As awareness of the term 2.0 begins to broaden, individuals are either becoming 
familiar with it, or they are still seeking to understand it. We plan to capitalize on the intrigue 
of the name to create early brand recognition and recollection. We also plan to emulate the 
familiarity of other popular 2.0 applications, with unique tools to meet the specific needs of 
the target market. It is imperative that early adopters find the site easy to access and navigate, 
and that it provides a wealth of highly useful information.  To accomplish this, two structural 
features will be employed. The first is the use of page restrictions and constraints, and the 
second is the development of specific architectural components to promote network effects. 
 
The first key structural feature of this site will be the development of format and 
constraints.  Web 2.0 does not have hard boundaries (O’Reilly, 2005) in that it is open to all 
users as a means to add value, but page constraints ensure ease of use. In his paper, The 
Cornucopia of the Commons, Daniel Bricklin (Bricklin, 2001) discusses the critical aspect of 
getting users to incorporate data into the site and create value. In one presentation, he refers 
to the structure of the user interface as being one of the most important ways to do this. Page 
constraints encourage users to focus on uploading and creating meaningful content, as 
opposed to becoming preoccupied with creative license. They are used to maximize 
download time and maintain site clarity. These ensure that users are able to find information 
and create connections quickly. The structural components are not intended to impede 
organizations in terms of uploading information, only that it be organized in a specific area.  
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  To illustrate how page structure and restrictions generate a user-friendly environment,  
a standard Facebook page is used (Figure 7). Facebook offers each user the same features; an 
area for picture, personal information, news, and activities.  Not only does this simple 
architecture provide a view of all accessible information at a glance for each individual, it 
ensures that  new users know exactly where to find the same information on another’s page.  
 
1. Picture / Logo  
8. Applications 
2. Specificities
3. News and 
other public 
information 
6. Friends / 
Acquaintances 
7. Advertisement 
4.  Images 
 5. Groups, Pages, 
or Hubs 
Figure 7 – A typical Facebook profile showing information constraints 
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 To compare a similar model for Pharma 2.0 it would result in numbered areas of the 
following: 
1. Corporate logo  
2. Corporate information, such as location, size of organization, public/private company, 
stock information, general therapy areas 
 
3. Public updates or news releases  
4. Corporate images, such as pipeline  
Pipelines are typically found on company web sites as images 
 
5. Hubs – therapy areas, development stage, industry event 
6. Partnerships / collaborations 
7. Advertising 
8. Applications such as search or other features, are often added by separate entities but 
are functional on the site. Outside applications would require pre-approval 
 
The above example is a simplified version of a potential layout, but provides a 
general idea of how constraints may be used to maximize the functionality of the site. Within 
these constraints, and as is common with free peer-to-peer networking sites, business 
professionals would be expected to develop their own company profiles4 and post 
information about their products and goals for global partnering. Once a user had established 
a profile, the organization would become part of the database allowing the company to be 
searchable. Organizations looking for partners would be able to enter search criteria using 
Boolean methods to enable them to locate and identify companies by industry, therapy area, 
stage of product development, location and executives. 
 
                                                 
4 During the launch period, Pharma 2.0 reps will enter company information to promote the value of network effect. 
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 Constraints would also be in place for advertisers. Pharma 2.0 will create a revenue 
stream through a traditional advertising model and advertisers will be limited by several 
requirements. First, they must be professional, legitimate and not contain any false 
statements. Second, the graphics and layout must be simple to prevent a cluttered appearance 
on the page. A single banner ad and/or search feature (Figure 7) would be appropriate. 
Finally, advertisers must be industry relevant. Each will be screened to ensure that they are 
compatible with the essence of the site. Examples of companies that might be targeted for 
advertising include: legal firms or specific IP firms, contract research organizations, 
equipment suppliers, consulting firms, conference organizers, travel-related companies and 
hotels. 
 
A clean, professional site builds client confidence and improves functionality. It is 
considered to be a critical component of development. The second architectural component 
of Pharma 2.0 will be to incorporate features that promote online network effects. If a site 
does not meet the needs of its intended network and it can’t provide them with a familiarity 
of people or events, then consumers are likely to move to another site that does. To promote 
network effects we must develop and sustain a base amount of users and the site architecture 
can contribute to this. One such functional feature is called a hub. Hubs are areas where users 
can locate others with similar interests or needs. Using these ‘centres’ can develop a network 
of peers that is less random, and has more appeal (Shuen, 2008).  Hubs are most effective 
when they mimic networking behavior that already exists in an industry. In the 
pharmaceutical / biotech industry, real-world hubs exist in several areas (e.g. therapy areas, 
development stages, location, market cap). For example, Figure 8 illustrates a hub for the 
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 therapy area – Cancer – and how this might enable two individuals to connect. Suppose 
Individuals 1 and 2 do not previously know each other. If each individual joins the therapy 
area hub “Cancer”, they will then be a part of each others’ networks and will make a 
connection. Users can explore fellow members of the group, make worthwhile connections 
and build their network. Using pre-established industry groups will provide a sense of 
familiarity and comfort in using the new technology and encourage direct networking. 
 
 
Figure 8 - Hub of a therapy area connecting individuals 
(created by M. Seltenrich, adapted from Shuen, 2008) 
  
A second architectural component that can help create a network are industry event 
areas where relevant information is located. Conferences are a standard event for pharma / 
biotech companies and offer one of the only places where executives can network with many 
other similar companies. Areas on the site that promote and link to industry events will allow 
users to find others that have attended similar functions, or are planning to attend. This 
feature is currently available through conference organizers and will be discussed in the 
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 competitors section further. To improve our customer services, we will make an effort to 
collaborate with conference planning organizations to provide additional aspects such as 
online meeting planners or registrations. 
   
The Shell 
In order to attract new users and maintain clientele, it is important to extend beyond the web 
site and offer a variety of products and services. Pharma 2.0 will include additional services 
to enhance client experience and utilize the abilities of management. These services are: 
Information news feeds, RSS feeds and white papers, consulting for merger / acquisition 
management, consulting for intellectual property law, online secure data rooms for private 
document exchange and registration competitions. 
 
Free information in the form of news and RSS feeds are common in the industry. 
Adding them to the site allows us to compete in another area and gives users a one-stop shop 
where they can go and complete all of their industry activities. These feeds can be delivered 
by email to prospective clients as a means of advertising. White papers are written on various  
issues within the industry. They can also act as a means of advertising, especially if we can 
get predominant individuals to contribute them to our site.  
 
The consulting activities of Pharma 2.0 will be developed as future add-ons. The 
management team has extensive experience in the fields of M&A, licensing, due diligence, 
partner negotiations and intellectual property law. Since the companies using Pharma 2.0 are 
most likely seeking collaborations like these, our experience may be sought to assist in patent 
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 filings, term sheets, negotiations, due diligence and deal close. We have the advantage of 
being able to advertise to our target audience, while our clients have services that are 
conveniently available. We expect that our services will eventually create an added revenue 
stream for the company. 
 
Virtual, secure data rooms will be offered to companies as a means of exchanging 
information during diligence processes. Traditionally, physical data rooms have been used 
during the process of merger or acquisition. Representatives of the merging or acquiring 
company are able to be on site in these rooms and review relevant data and information. This 
can present difficulties in logistics for both the visiting and host organization. Physical areas 
or resources may not be available, travel might be costly or security may be an issue. Virtual 
rooms offer a chance to exchange information online rather than have individuals physically 
visit the company. The advantage is that logistical resources are not necessary and 
organizations can focus on evaluating the information. Online data rooms will be established 
with a login and password and so that the two groups can exchange information in a 
completely secure manner. 
 
Competitions on the site may be introduced. These would most likely be give-aways 
for conference registration and would be made available early-on in the product life cycle to 
help build critical mass. The purpose of these competitions would be to get users to sign up 
for the site. Announcements would go out informing users that sign up to the site would 
automatically enter their names for registration draws. This may also provide the opportunity 
to partner with conference planning companies and exchange the registration for advertising. 
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 4:  COMPETITIVE ANALYSIS 
 
A thorough competitive analysis is fundamental to developing a strong business strategy, and 
ultimately creating a profitable enterprise (Grant, 1998). While, it is necessary to review the 
strength of the direct competition (companies that provide the same service), it is also 
important to review the competitive forces at the industry level (Viardot, 2004). In his book 
Contemporary Strategic Analysis, Robert Grant describes Industry as “a group of firms that 
supplies a market” (Grant, 1998). Awareness of all relevant competition within an industry 
ensures that key relationships are not missed or underestimated. Underestimation of a 
competitive landscape can certainly lead to a corporation’s failure, particularly in the 
dynamic world of high-tech firms. 
 
We conducted a competitive analysis for Pharma 2.0 and broke this out into four 
sections. First, Table 2 provides an overview of the direct competitors. Second, these 
competitors are  further profiled to determine differentiation. Third is a review of the industry 
using Porter’s traditional five forces model. And fourth, a more detailed look at the 
substitutes is provided.  
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4.1 Direct Competitors 
 
Direct competitors are those firms that offer similar products and/or services (Grant, 1998). 
For Pharma 2.0, direct competitors are considered to be the companies that provide the 
following: A business development web portal, unique to the pharmaceutical / biotechnology 
industry that requires a company registration and profile, provides industry relevant 
information in the form of news and events, and promotes communication for the sake of 
forming collaborations (mergers, acquisitions, licensing). 
 
Within this industry there are many organizations that provide access to free online 
information such as news feeds or RSS services, but there are few that specifically target 
partnering activities. Three sites have been identified that are considered to be direct 
competitors to Pharma 2.0. These are Pharmalicensing, MyBioPartner, and Bio-Network. 
Figure 9 is a competitor overview showing the features of Pharma 2.0 in comparison to these 
three competitors. Pharmalicensing is clearly the strong competitor based on features.  
Differentiation will be highly dependent on the cost to utilize the service and the network 
effects we can build and sustain through the marketing strategy. 
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     Figure 9 - Comparison of direct competitors 
 
 
4.1.1 Pharmalicensing (UTEK)   
 
Pharmalicensing (www.pharmalicensing.com) is the current leader for online pharma / 
biotech business development and partnering. The company was acquired by UTEK 
Corporation in January 2008. UTEK is an innovation services company that offers assistance 
to organizations who wish to add value to their intellectual property. UTEK is publicly traded 
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 on the NASDAQ and has a market cap of approximately $363 million. It is headquartered in 
Tampa, Florida with offices in Chicago, IL, Phoenixville, Pennsylvania and York in the U.K.  
The company’s current strategy is to acquire organizations that have an open model for 
innovation. In the three years up to December 2006, UTEK made six acquisitions of 
companies in the open innovation field (UTEK Annual Report, 2007). Financial statements 
as of December 31, 2007, showed the company had achieved $20.3 million in revenue, a net 
income of $3.8 million, and a cash position of $5.3 million. It is noted that the cash position 
will not likely affect future acquisitions, as the company completes most of the acquisitions 
through equity shares (UTEK Annual Report, 2007). 
 
The Pharmalicensing web site is designed to assist in intellectual property 
development for  university, research laboratory and corporate technology in the life sciences 
industry (Pharmalicensing, 2008). The site is a resource for partnering, licensing and 
business development professionals and claims to have approximately 100,000 visitors per 
month. Although the site has a free service that allows visitors to search for companies, any 
further participation requires a paid subscription. The subscriptions range from 
approximately $1,800 USD for an individual user up to $8,000 USD for 10 users within one 
organization. Figure 10 shows the page layout and functions of Pharmalicensing. 
 
 
 
 
 
 41
 Categories  
 
s 
Jobs, 
News, 
cases,  
etc. 
 Search areas by 
industry sector or 
therapy area 
Search by keyword
t 
 
  
 
Figure 10 - Standard Pharmalicensing page for licensing ac
 
 
Pharmalicensing provides most of the same functions that Pharma 
and is well established and well financed. Boolean operators5 provide cros
searching by categories such as industry, therapeutic target and phase. We
is a strong competitor to our company. One of the key differentiators we h
is a substantial fee to pay for the services. However, we also acknowledge
                                                 
5 Boolean operators are search functions that are used to combine keywords with words like AND, OR and NO
search results (Leger, 2007). 
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 organization could lower or change its cost structure and advertising model relatively easily. 
Therefore we will capitalize on being based in North America and promoting services 
specific to the region. For example, one area noted for servicing the UK, is the job search on 
Pharmalicensing. While there are many European jobs featured, there are only 2 North 
American jobs. This may be one feature we could add that would be more specific to Canada 
and the USA.  
 
4.1.2  MyBioPartner   
 
MyBioPartner (www.mybiopartner.com) is advertised as a free web site that offers a 
comprehensive list of biotechnology companies seeking partnerships and collaborations. It 
also promotes assistance with financing for start ups through VCs, Angel investors and 
investment banks. It is difficult to determine where the site originates from, as all employees 
are listed by email address only.  
 
MyBioPartner alleges to have 3500 registered companies worldwide but a standard 
search of the site revealed that the company has taken the liberty to add organizations 
themselves, without attention to accurate information. The errors in information were 
determined by reviewing several of the organizations and comparing these to current news 
releases and web sites. While MyBioPartner is a fit according to the criteria for direct 
competitors, registration does not allow access to any data, and you must pay approximately 
$15,000 - $20,000 USD to access anything further. Therefore, due to what we consider false 
advertising, the organization is not seen as a significant threat to Pharma 2.0. 
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4.1.3 BIOTECH Network  
 
Biotech Network (www.biotech-network.com) is an international partnering web portal run 
by the German-American Chamber of Commerce in California. This not-for-profit site offers 
a place where organizations can create a profile and look for partners. The site also provides 
links to the top conferences so members can see who is planning to attend. 
 
Biotech-Network has very few features and many of the links on the site did not 
work. This poor structure and lack of proper maintenance makes it  difficult for companies to 
use effectively for partnering activities.  The site is also missing the majority of our proposed 
elements meaning that industry users would have to create multiple registrations in other 
areas if they want to get news feeds, RSS, conference info or consulting services. As such, 
we do not see this site as being a strong competitor. 
 
4.2 Porter’s Five Forces 
 
The competitive landscape for Pharma 2.0 was reviewed using Porter’s Five Forces model. 
The model analyses a company’s industry environment by five factors and rates them as 
either high or low. These factors are: the threat of substitute products, the threat of entry, the 
bargaining power of customers, the bargaining power of suppliers, and the intensity of rivalry 
among competitors. Figure 11 is a graphical representation of the five forces as applied to 
Pharma 2.0 illustrating which of these are considered to be the high and which are low. 
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Figure 11 - Graphical representation of 5 forces for Pharma 2.0 
(created by M. Seltenrich, adapted from M. Porter) 
 
4.2.1 The Threat of Substitute Products 
 
The threat of substitute products refers to buyers’ willingness to pay for one product when 
another offers a similar benefit. If the cost of one should increase, the inclination of the 
customer to switch to the alternative increases and the demand for product is considered 
“elastic”. If there are few substitutes, then consumers are not affected by price (e.g. 
cigarettes) and the item is referred to as “inelastic” (Grant, 1998).  
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 The threat of substitute products in this industry is high. Since our customers do not 
pay for our site, switching behavior will more likely be influenced by the level of effort 
required to maintain the corporate profile on the site, and whether they have success finding 
partnerships. The presence of substitutes in the industry is so significant that this section is 
followed by a more detailed description of them. A strong, ongoing marketing strategy will 
be critical in building and maintaining the user base, and differentiating Pharma 2.0 from 
substitutes. A comparative evaluation of the substitute products has shown the following 
ways in which we can promote differentiation: 
• Current substitutes are considerably more expensive  
• Level of differentiation from Pharma 2.0 is regarded as high, since the reason 
preventing most companies from using other sites are the costs involved 
• Conferences require numerous resources (time, money, employees) 
• Individual networking (e.g. cold calling, previous contacts)  is limited by an 
individual’s connections and these may not fit with the organizational strategy. 
• Consultants are also extremely costly and will be limited by their networks 
 
4.2.2 The Threat of New Entrants 
 
It is inevitable that profitable markets with high returns will bring new entrants. Unless the 
entry of new firms can be blocked, the profit rate will fall (Grant, 1998). Most of the time, 
new organizations will find it difficult to enter a market on the same level as those already 
established in the industry. The difficulties encountered are referred to as “barriers to entry”. 
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 These barriers include such things as: capital requirements, economies of scale, cost 
advantages, product differentiation, and legal barriers (Grant, 1998). 
 
In this market, the threat of entrants is considered to be high. The web based format 
of the business makes it relatively easy for others to copy it or for companies already in the 
business to create a similar application. For example, a company like Facebook or Google 
that already has an advantage in terms of technology platform, infrastructure and brand 
recognition could pose a significant threat for creating a business to business type application 
in the pharma industry. Patentability is also low compared with other industries, or products. 
The ways that we will attempt to block competitors and maintain our position in the industry, 
is as follows:   
• First mover  
• No cost for registration and partnering activities 
• Managements’ education and experience 
• Numerous site add-ons and features 
Even considering these features we offer, there will still be a threat of entry. These points 
may minimize it somewhat but ultimately, what will matter is how well we are able to attract 
and maintain participants. If we can accomplish this by continuing to meet our customer 
needs, then we can build a network value that will act as a strong barrier to entry. 
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 4.2.3 The Bargaining Power of Customers 
 
The bargaining power of customers refers to their ability to put pressure on the firm and their 
sensitivity to price changes. Customers are, in essence, where the value of this business lies 
because it is the network that adds value. The more users the site has, the more valuable it 
will become. Companies that utilize Pharma 2.0 will be able to put pressure on the 
organization with the threat of switching to other free sites if any should arise; which is 
possible due to the low barriers to entry (see section 4.2.2). Another significant force that 
could fall within this category is the bargaining power of advertisers. Advertising is the 
means by which we will create a revenue stream. If advertisers are not willing to pay the 
price we’ve established to run ads, then the site will not continue as a free resource and 
revenue will have to be achieved by some other means. In order to reduce these threats, the 
number of users, and therefore the value of the site must be maintained. With a high value, 
user options will be reduced and the power will shift to the organization. Some of the ways 
we plan to maintain our power are: 
• Continuously reaching out to the product’s target market (s) 
• Offering add-on features such as conference links, news feeds, competitions 
• Maintaining a highly professional level of service 
 
4.2.4 The Bargaining Power of Suppliers 
 
Suppliers of raw materials, components, and services (such as expertise) to the firm can have 
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 a level of power (Grant, 1998). Suppliers may refuse to work with the firm, or charge 
excessively high prices for unique resources, the net income of the organization will suffer. 
One of the critical inputs to our business are the IT services. Server size and functionality 
must be appropriate for the amount of traffic the site generates, and this must be maintained 
well at all times. Gaps in service or slow server times could deter customers from the site, 
complicate site media reviews, and seriously affect revenue. Selection of IT services will be 
well researched if outsourced, but this function may be brought in-house as a third partner. 
Bringing in a partner to manage the IT portion of the business will ensure that there is an 
equal investment at stake and will provide reassurance that service will be maintained 
appropriately. Even without this, IT components are critical to the success of many 
companies, and the supply is not highly limited or highly specific. Therefore, this force is 
considered to be low in comparison to the other four.   
 
4.2.5 The Intensity of Competitive Rivalry 
 
For most industries, the rivalry between companies determines the basis of competition. In 
some cases, rivals compete aggressively on price or cost, and in others, it is a non-price 
element such as innovation or marketing (Grant, 1998).  
 
For industry relevant companies that research information for distribution or create 
forums for networking, there are two ways that they rival one another. One facet of 
competition is price, another is the quality of the information or the event. Because the 
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 market intelligence subscriptions are heavily utilized to create both corporate and business 
strategies, the level of quality becomes extremely important. Our price is not a factor, so we 
will compete on the aspect of quality. As such, we’ll need to ensure that the information 
available on the site is valuable and is delivered in a professional and user-friendly manner. 
We see the competitive rivalry and our advantages as follows: 
• Not enough direct competitors to create strong rivalries 
• Companies that are present require paid subscriptions 
• Professionalism will be maintained through appropriate screening techniques (e.g. 
relevance of organizations and advertisers) 
• Information distribution will be controlled through interface constraints 
 
4.3 Substitutes  
 
Indirect competition is the greatest threat to Pharma 2.0. Industry executives are accustomed 
to utilizing systems already in place for business to business communication and networking. 
This section has been included to provide a more in-depth look at some of the most 
threatening substitutes, including:  event planning organizations, consulting companies and 
investment banks.   
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 4.3.1 Partnering Event Planners / Organizations 
 
Conferences are the most significant means of business development in this industry. There 
are several companies that plan these events. Prior to each conference, the organizing group 
creates a database for registered participants to upload information about themselves as a 
means of advertising for partnerships. The information typically includes a corporate profile, 
the names and titles of attendees, an email service, objectives for the meeting, and any 
products that are available for in or out-licensing. Three of the leading event planning 
organizations have been profiled. These are: BIO, Technology Vision Group, and 
BIOTECanada. 
 
BIO is the world's largest biotechnology organization, providing advocacy, business 
development and communications services for more than 1,150 (company) members 
worldwide (www.bio.com, 2008).  BIO members are involved in research and development 
of innovative healthcare, agricultural, industrial and environmental biotechnology 
technologies. Corporate members range from entrepreneurial companies developing a first 
product to  multinationals (www.bio.com, 2008). Member services include a dozen or more 
investor and partnering meetings throughout the year, a web site and communications 
services that disseminate information and discounts for a variety of goods and services. There 
are approximately 14 annual events for Bio that attract a massive number of attendees. The 
International convention that is held, is the largest biotechnology industry conference. This 
massive event attracts more than 20,000 attendees from around the world including more 
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 than 500 members of the international press. Guest speakers have included Bill Clinton and 
Samuel L. Jackson. 
 
Technology Vision Group (TVG) is one of the leading international life science 
business development organizations. Founded in 1992, the company has succeeded in 
bringing companies together with partnering conferences, research tools and time 
management software. TVG also offers business development consulting services and 
marketing support. TVG has been developing innovative methods to help life science and 
associated technology companies attract partners and investors, acquire new products and 
technologies, and achieve a variety of other strategic business development goals. A 
successful 15-year track record of success makes TVG one of the most senior life science 
business development firms in the world. 
 
TVG sponsors Biopartnering.com, the online partnering tool that enables participants 
to schedule and prepare for private meetings before attending a conference. Once registered, 
company delegates can access the password protected area of the site to research partnering 
opportunities through keyword searches and detailed profiles on all companies. The site 
enables contact of other delegates to arrange private meetings and reserve meeting space at 
an event. TVG holds approximately 5-6 annual events with as many as 1000 companies in 
attendance to some. Biopartnering.com is a very similar web portal to the envisioned Pharma 
2.0 and possibilities for collaboration with the company will be explored. 
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 BIOTECanada was incorporated in 1987 as the Industrial Biotechnology Association 
of Canada. It is a national, industry-funded association representing the broad spectrum of 
biotech constituents including emerging, established and related service companies in the 
health, agricultural, and industrial sectors. BIOTECanada is dedicated to the sustainable 
commercial development of biotechnology in Canada. The goal of BIOTECanada is to 
inspire the international community to recognize the value of biotechnology in Canada and 
provide solutions to challenges. BIOTECanada offers updates on the most relevant partnering 
meetings, as well as special offers for registration (BIOTECanada.com, 2008). 
4.3.2 Consulting Companies / Investment Banks 
 
Consulting companies and investment banks can assist organizations in locating partners for 
mergers and/or acquisitions. While strictly using consulting companies can be costly, 
investment banks will often work with an organization to help locate funding that will follow 
the merger. This can be a highly effective way to target potential opportunities, and increase 
chances of financing. There can be the added advantage of fees being subject to a deal close. 
One of the downsides to using consultants and investment banks, is that they can be limited 
by the number and/or type of contacts they have and will occasionally miss opportunities. 
The above substitutes represent a significant threat to this business. An online, open business 
model does not have the same protection against competitors that a traditional (product 
oriented) business has. To gain a competitive advantage, Pharma 2.0 can do one of two 
things; it can supply products or services that are different from the direct competition and 
the substitutes, or it can pursue a cost advantage (Grant, 1998).  
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  With our free web site, we have chosen to pursue a cost advantage, but we also plan 
to remain at a high standard of product quality. According to Robert Grant, author of 
Contemporary Strategy Analysis, firms that compete on low cost are distinguishable from 
firms that compete in areas of market position, resource, capabilities and characteristics 
(Grant, 1998). Pharma 2.0 will be differentiated from competitors by its free access and its 
ability to act as an “industry centre” where executives can go to complete numerous 
functions in one place. In terms of market position, resources, and capabilities, we may not 
be able to compete and this could have a significant impact on competitive advantage. Our 
most admirable competitors are high cost and high quality, and in such a traditional industry, 
it is possible that executives will not view a free application as valuable and hesitate to 
register due to concerns of quality or security. These issues will be addressed through our 
marketing strategy. 
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 5:  MARKETING STRATEGY 
Pharma 2.0 is a high-tech product, dependent on network effects. As such, marketing is an 
imperative component for generating awareness and establishing a position in the industry.  
Though many of the objectives of marketing remain the same across products and services, 
high-tech products require clear communication and assistance in learning the product, and 
an ability for management to maintain a position in a rapidly changing environment (Viardot, 
2004). The goal of our marketing strategy is to introduce the product to our target market in 
an effective and clear way, that can generate a strong interest and help us move up the 
adoption curve.  
5.1 SWOT Analysis 
 
Pharma 2.0 has potential to be a breakthrough opportunity. Business development executives 
are currently using other technologies at a much higher cost to achieve the same results we 
can offer. It is important to note that this is not a traditional product-based company and that 
a 2.0 business can only gain a competitive edge and form barriers to entry by creating and 
maintaining a strong network  (Shuen, 2008). To better understand our strengths and 
weaknesses and how these relate to our environment. A SWOT analysis has been conducted 
to evaluate the internal and external environment for Pharma 2.0 (Table 1).  
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 Strengths 
- 1st site of its kind to offer all functions for 
industry professionals in one place 
 
- The site is completely free for those users 
that are seeking pharmaceutical / biotech 
collaborations 
 
- A management team with diverse skills,  
strong industry connections and good 
reputations in business development and 
intellectual property law. 
 
- The number of mergers, acquisitions and 
licensing in this field continues to trend up 
 
Opportunities 
- Massive industry ($600+ US billion) 
- 2.0 applications have proven highly 
successful in other areas of networking (e.g. 
Facebook) 
 
- There is a communication gap between 
start ups and small companies and large 
potential partners 
 
- 2.0 applications are becoming a hot area 
and many senior executives are eager to take 
advantage of them 
 
- Many up and coming executives are from 
younger generations that are accustomed to 
using these kinds of applications in their 
daily lives (e.g. MySpace, Facebook, Flickr) 
 
Weaknesses 
- Currently there is no IT component to the 
company. This will either have to be 
outsourced or a third partner will be brought 
in  
 
- 2.0 is not well utilized in the pharma / 
biotech industry and many companies prefer 
a traditional way of doing things 
 
- It is difficult to get patent protection on a 
site like Pharma 2.0 
 
Threats 
- There are few if any barriers to entry for an 
open site 
 
- Other strong organizations that already 
have a platform and a brand recognition 
could easily transfer into the industry 
 
- The user community is completely 
dependent on network effects and without 
these, it will be difficult to establish users for 
any other reason 
 
- A shift in technology could eliminate the 
use of 2.0 sites in the future 
 
 Table 1 - SWOT Analysis for Pharma 2.0 
 56
 SWOT Analysis for Pharma 2.0 
 
Evaluation with the five forces and the SWOT analysis, confirms that external threats to the 
company are strong. Users can switch to our direct competition, or to various substitutes  and 
competitors can surface easily due to low barriers to entry. However, something that is 
particularly favorable for us is that rivalry in the current environment is low. If we can enter 
the market strongly and stay aggressive in maintaining a position, we’ll have an opportunity 
to develop a brand and user base that can move up the adoption curve to a critical tipping 
point (the point at which the network effects drive the business). Strong product 
communication will be necessary, as will support and client follow-up. Consistent 
professionalism in the quality of the site and in our services will help reassure consumers 
who are hesitant to join a free networking site. However, it will be difficult to attract 
advertisers before we have established a critical mass of users. Therefore, the plan does not 
include targeting this group.  
 
 Research on successful 2.0 organizations shows that one of the methods for creating 
strong networks is to start by attracting communities (Shuen 2008). Once a community 
establishes an online environment, it will likely attract another community and so on. An 
example of this is Facebook. In February 2004, Facebook was launched as a social site for 
Harvard University students. Members of the initial community connected with students 
from other universities who wanted to become participants and eventually several Ivy league 
schools picked up the application. The site then moved to high schools, and eventually 
opened up to the Worldwide Web in the Fall of 2006 (Shuen, 2008).  
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 Our marketing approach will be to use a similar method of segmentation into 
communities within the pharma / biotech industry. Segmentation is already present in the 
industry and is determined mostly by size, pipeline / products, and revenue. We’ve utilized 
the common segments. 
 
• University tech transfer offices 
• Start-up / spin-off organizations 
• Small biotechnology / biopharmaceutical companies 
• Medium biotechnology / pharmaceutical organizations 
• Large biotechnology / pharmaceutical companies 
  
 University tech transfer offices manage relationships between their academic 
researchers and industry partners by creating agreements for the intellectual property that has 
been created in the labs. Many start-ups are spun out of universities because researches that 
have created intellectual property want to benefit from the value themselves, rather than seek 
an industry partner. 
 
 Most start-up organizations have limited funding to dedicate to their research, let 
alone to dedicate to finding partners. We will combine the group of universities, start-ups and 
small biotech companies to create a beachhead market segment. A beachhead is a niche 
market that you allocate all resources to in order to obtain a leadership role (Moore, 1991). It 
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 simplifies and centres the marketing strategy. All marketing will initially be focused on the 
target market only as it is expected that initial resources will be limited. However, as the 
critical mass builds, these same methods will be used to target industry relevant advertisers 
for the site. This will come as a secondary market since it is assumed that there will be little 
to no interest from advertisers before the site has established. 
 
5.2 Targeting the Beachhead 
 
The target market consists of universities and small organizations that do not have resources 
to commit to partnering activities. Marketing to a segment is about creating word-of-mouth 
leverage and becoming a market leader. Both critical components of high-tech marketing in 
the early stages (Moore, 1991).  This target market is considered to need a very specialized 
product or an unsought product. This means that to manage their tasks, they require a 
specialized product for which price sensitivity is low, or they are not aware of the product at 
all. Since these companies do not have extensive resources and do not currently have a free 
option for partnering, we will classify our product as unsought (Wong, 2005). An unsought 
product should be introduced to the target market in places where similar products or needs 
are located (Wong, 2005). This segment has relatively less resources and so likely uses the 
Internet to post their technology and to search for partner organizations. They may also 
attend some conferences to present data and locate partners.  
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  The launch of the site will be at an industry conference, possibly Biopartnering North 
America in Vancouver, and will consist of a reception event / cocktail party at which we will 
introduce both ourselves and the product. For a limited time, we’ll offer our services to input 
information into the database with follow-on services such as technology updates, partner 
leads and consulting services. These will be offered to preliminary organizations (e.g. first 
500 companies) only as a means of building a critical mass. Following our launch party, 
we’ll begin our other forms of marketing. We plan to implement a strategy that will allow us 
to reach the most customers at a low cost. To do this, we’ll use a combination of advertising 
methods and networking opportunities. These are: Seminars and workshops, E-marketing,  
Conferences, Trade publications, Memberships, and Government Consulates. 
 
 
5.2.1  University Seminars & Workshops 
 
A variety of seminars and workshops will be offered to university tech transfer offices and 
local biotech companies. The seminars will take place at campuses in Vancouver and the 
lower mainland, Alberta and eventually into Washington. These will also be open to local 
organizations. The seminars will provide an overview of the market, the product and 
instructions on how to use it.  
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 5.2.2  E-marketing 
 
E-marketing is often used for high-tech products with low cost and can be efficient in 
replacing a sales force (Viardot, 2004). Our approach to this type of marketing will be 
through various forms of information feeds, such as: news feeds, RSS feeds, webinars, white 
papers and conference information. Webinars are free, online services in which consumers 
can sign up for a seminar that takes place online and is viewed on the consumer’s monitor. 
These are highly attractive to executives because they provide free information and the 
viewer never has to leave their office. Providing ongoing services like these can draw in a 
community who become familiar with the company by using the information sources 
entering their email. Eventually if they wish to pursue the services we offer, they will be well 
aware of our organization. 
 
5.2.3  Conferences  
 
Pharmaceutical conferences are held globally throughout the year. They are the most utilized 
form of networking in the industry and are held at a variety of select locations. The 
conference circuit provides executives with a forum for presenting their companies, their 
products and services, and their most recent research. There are seminars, workshops and 
open floor / trade areas where booths can be set up. There are also one-on-one private 
company meetings, sponsored dining, and evening receptions.  We are experienced with all 
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 of these areas within the pharmaceutical conference circuit and will use each of them to 
promote our company. 
  
 However, as noted earlier, conferences can become extremely expensive - particularly 
when there is travel involved and they will have to be limited to a few per year. Having spent 
many years in a business development and legal environment, we are aware of which 
conferences attract the most participants and are the ones that can provide us the best arena 
for our presentations. Attending these meetings will be the most valuable way for us to 
introduce our product to new clients, to interact with our current clients and to receive 
feedback. 
 
5.2.4  Trade Publications 
 
Some of the more common trade publications used in the industry are: MedAd News, 
BioPharm International, Nature Biotechnology and BC Biotech. Ads in trade publications 
may be purchased, however, this is can be a very costly form of advertising and will only be 
used occasionally. For example, advertising in MedAd News can range from $1,300 USD for 
a small black and white ad in one issue, up to over $16,000 USD for a full page color spread 
(MedAd News, 2008). 
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 5.2.5  Association Memberships  
 
We are members of several organizations that we can leverage to create opportunities in 
North America. Some of these are: The Licensing Executives Society (LES) of USA and 
Canada, BC Biotech, Vancouver Enterprise Foundation, and BIO. These organizations 
arrange meetings and events throughout the year in order to provide a networking 
opportunity for members. They often hold small speaker series and panels as introductions to 
new companies and entrepreneurs. These memberships will provide access to 
communication, networking and support for our business. 
 
5.2.6  Canadian  Trade Commissioner Service 
 
The Government of Canada provides services that help Canadian companies do business in 
other countries. Trade commissioners are located in 150 cities around the world to assist 
companies in finding contacts and making connections with organizations (Canadian Trade 
Commissioner Services, www.infoexport.gc.ca,  2008). Having been in positions of business 
development and law, we have made connections with many of these representatives in the 
past and will use those to assist in getting foreign introductions and contacts for our site. 
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 6:  MANAGEMENT & EXECUTIVE TEAM 
The management team of Pharma 2.0 is one of the key strengths of the company. The two 
founding members, Ms. Susan Ben-Oliel and Ms. Michelle Seltenrich have considerable 
experience in the pharmaceutical and biotechnology industry, especially in the areas of 
managing partnering activities and intellectual property. The founding team will be 
responsible for locating funding and setting up the organization within the first six months to 
a year.  
 
 In Q4 2009, a sales team will be established to assist in promotional materials, events, 
and to maintain advertising on the site. This team will consist of two employees working on 
base salary plus commission and will expand as necessary. We’ll offer industry comparable 
salary packages, benefits and possibly stock options. Another position that may be 
considered following the first year is an executive IT professional. This position will be vital 
if managing the relationship with the organization responsible for IT has become too 
demanding for management, or if the company is in a position to vertically integrate and 
bring the IT component in-house. The latter will only be considered if the organization is in a 
financial position that is much stronger than anticipated. 
 
 
 64
 6.1 CEO 
Susan Ben-Oliel, BSc LLB 
Ms. Ben-Oliel is an Intellectual Property Lawyer and Registered Patent and Trade-mark 
Agent and has held the position of Senior Director, Intellectual Property at Forbes Medi-Tech 
Inc. since November 2005. Prior to joining Forbes, she operated her own law practice from 
1997 to 2005. Ms. Ben-Oliel specializes in preparing, filing and prosecuting patent 
applications, performing technology audits and due diligence, providing technology 
protection and exploitation strategies, licensing, transferring and enforcing patent rights in 
the biotechnology sector, along with preparing commercial contracts including license 
agreements, service agreements, supply and distribution agreements, research agreements 
and confidentiality agreements. She was employed by and subsequently worked on contract 
for the law firm of McCarthy Tetrault in Toronto and Vancouver from 1988 to 1997.  
 
Ms. Ben-Oliel holds an undergraduate degree in Life Sciences from Queen's 
University, a Bachelor of Laws from the University of British Columbia, is a Registered 
Patent Agent in both Canada and the United States and is a Registered Trade-Mark Agent in 
Canada. 
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 6.2 COO 
Michelle Seltenrich,  BSc, MBA, CFA  
 
Ms. Seltenrich comes from a career in pharmaceutical and biotechnology corporate 
development. She has management experience in internal strategic planning and forecasting, 
research and analysis of  mergers, acquisitions, licensing, and external business development. 
Ms. Seltenrich specializes in the analysis and recommendation of merger / acquisition 
opportunities and the management of due diligence activities. 
 
Ms. Seltenrich received her Bachelor of Science degree from the University of British 
Columbia. She completed her Graduate Diploma in Business and her Management of 
Technology MBA at Simon Fraser University. Ms. Seltenrich has most recently entered into 
the CFA Institute and will complete Level 1 in June 2009. 
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 7:  FINANCIAL PLAN 
 
The Pharma 2.0 financial plan has been developed conservatively in order to take into 
consideration the risk involved in this type of venture. The start-up cost is $500,000. 
Something we feel is achievable through grant funding and personal contribution (i.e. 
ourselves and friends/family network). Web 2.0 companies are not overhead intensive and 
initial funding is for building and maintaining the web site and supporting promotional 
activities. This strategy will allow us to remove the risk of having venture capital or angel 
investment in the first year. 
 
7.1 Start-up financing and revenue 
 
Start-up costs have been calculated at roughly $500,000. This consists of $50,000 for a site 
design, $200,000 to outsource the development and maintenance of the site and the 
remainder put towards growth. Reduced salaries ($50,000 per employee) will be taken in the 
first year, but resources are required for market intelligence subscriptions, conference 
attendance and travel expenses. If enough grant funding cannot be obtained to start the 
business, the next step will be to seek VC or angel investment. Ideally, we will not seek this 
type of funding until we have established a user-base, which is forecast for 2010. 
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 The Government of Canada and British Columbia have created incentives to assist in the 
development of the biotechnology industry (Life Sciences BC, 2008). There are also various 
organizations dedicated to science and technology, and in particular, women in technology. 
The following are organizations we will submit grant applications to. 
 
• NSERC – Natural Sciences & Engineering Research Council 
• CIHR – Canadian Institutes of Health Research 
• SCWIST – Society for Canadian Women in Science and Technology 
• Science Council of BC 
 
 Some revenue may be seen in Q4 of Year 1, but more significantly in Year 2.  The 
site will generate revenue through an advertising model similar to the traditional media 
advertising found in magazines or on television. This type of model works best on sites 
where there is a high volume of traffic, or where there is a highly specialized audience 
(Rappa, 2008). As we have a very highly specialized audience and industry-specific ads 
running, we are confident that our revenue will sustain the business. Advertising will only be 
open to industry-related companies such as legal firms, CROs, equipment manufacturers and 
suppliers, or travel ads (due to the extensive need to travel in the industry). 
  
 Ad pricing will be a standard media format. Unlike most Web 2.0 applications, this 
will not be a pay-per-click or pay-per-view model. In a highly specialized online 
environment, the user base is not large enough to uphold the pay-per-click model. Instead, a 
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 contextual and traditional advertising model will be used. By contextual, we mean that ads 
are specifically targeted to users, and therefore have a higher chance of generating leads, and 
by traditional we mean similar to magazine or television models. Advertisers will be required 
to pay a fee based on the type and size of the ad displayed on the page. Two banner sizes 
have been established, a large banner ad will run for 1 month and cost $5000 (views will be 
as per 1000), a small banner will run for 1 month and cost $2500 (views will be as per 500). 
Views will be calculated and refunds will be provided for those not reaching 1000 or 500 
respectively. Cost of ads has been established by estimating the number of viewers and 
comparing this to other traditional media sources. While it is difficult to determine exactly 
how many views the ads will receive, we can look some of the competition to establish an 
estimate. First, our direct competitor, Pharmalicensing has nearly 10,000 companies 
registered, and claims to have over 100,000 visitors each month (Pharmalicensing, 2008). If 
we estimate meeting half the amount of views, it would provide us with 50,000 unique page 
views per month. We now relate this number to traditional advertising using the industry 
specific magazine Med Ad News. Med Ad News reaches approximately 10,000 readers per 
month (Canon Communications, 2008). Depending on the size and color combination of the 
ad, prices for a one-month advertisement range from approximately $1,100 USD up to over 
$16,000 USD. Given that we anticipate the potential for a five-fold audience, we feel our 
prices are well within an acceptable cost range. 
 
 Advertising in the form of full webinars or white papers will be established in year 2. 
Companies wishing to run a webinar video on the site will pay $25,000 to run the video with 
full promotional package. Promotions leading up to the webinar will be disseminated for one 
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 month prior in a daily news feed and will receive constant promotion on the site via a posted 
link for information.  
 
7.2 ProForma Financials  
 
Pharma 2.0 financials were produced by reviewing similar organizations and creating 
averages, as well as by estimating our specific business services and needs. Appendix 1 
shows the assumptions that have been made for the forecast model. Sales growth rate was 
established by reviewing two public Web 2.0 organizations, one highly successful, and one 
start-up. The exceedingly high growth rate that appears after the first year is common for 
these kinds of web sites, and is a result of building the critical mass (5-20% of final users) 
and tipping the market so that the network effects generate the growth. Following this rapid 
growth will be a levelling period.  
 
 All other assumptions were created on a percent of sales basis. Materials are expected 
to be low in a web based organization that does not have manufacturing. General and 
administrative amounts are based on head office activities, which are also expected to be low 
for the organization with few employees. Commission sales will start in 2010 when two 
employees will be brought in to sell the advertising space. They will have a base salary of 
$40,000 to start and commission of 10% on their individual sales. Marketing in the first year 
is expected to be significant as introduction of the site and our services is essential to getting 
our user base established.  
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 7.2.1  Notes to Financials 
 
Notes 1 through 8 have been added to assist in understanding the proforma financials for 
Pharma 2.0. 
 
1. Revenues have been calculated by reviewing two Web 2.0 public companies (as 
mentioned earlier), one hypothetical forecasted model for an internet start-up (PaloAlto 
Software, 2002), and several online magazines with similar advertising models. In the first 
year, it is expected that we will spend all of H1 building our user base and will not seek 
advertisers. The overall total user mass for the site is difficult to estimate as it will be open to 
all employees in the life sciences industry. It is estimated that it could reach up to several 
hundred thousand users. However, for our estimate, we will use a total of 50,000 users to 
estimate our 5-20% critical mass. Therefore the minimum of 2,500 companies will have to be 
entered into the database to begin moving users up the S-curve. As an introductory 
promotion, we’ll enter the first 1000 users free of charge. Following this, individuals wishing 
to join will have to create their own profiles. In H2 of the first year, we will begin to seek 
advertisers to generate revenue.  
 
2. Worst case, most-likely and best case scenarios have been established to determine the 
amount of revenue that could be generated for the 6 months. The most likely case6 has been 
used and consists of establishing 2 large banners per month for 6 months at a cost of $5,000 
                                                 
6 Estimates for revenue are subject to change if, upon expert review and opinion, the first model for advertising is not valid and a second 
model must be implemented. 
 71
 each and 8 small banners per month for 6 months at a cost of $2,500 each. No webinars or 
white papers have been included in the estimate.  
 
3. Marketing expenses are anticipated to be high in the first year, and have been set at 
$110,000. The expenses in the second and third years of business are based on a percentage 
of sales set at 15%. Expenses include conference registrations, tradeshow booths, travel,  
marketing brochures and other promotional materials. 
 
4. Market intelligence refers to the subscriptions and reports that will be purchased to 
maintain the news and information feeds on the site. It is critical to establish a level of trust 
among users and the information that is on the site and that goes out in emails must be 
correct.  
 
5. Other operating expenses refers to rent of office space in downtown Vancouver, and other 
operational expenses such as utilities. 
 
6. Loans are not anticipated therefore interest will not be calculated for years 1 – 3.  
 
7. Taxation under British Columbia small business act will be 15% for revenue under 
$400,000 annually and is expected to rise to 35% with increasing revenue in the years 
following. 
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 8. Intangible value of employee knowledge and web site that has generated an ongoing 
network of users. 
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 8:  EXIT STRATEGY 
 
The exit strategy is by acquisition in either Year 3 or Year 5. This strategy is considered 
characteristic for Web 2.0 start-ups. Unlike earlier dot.com companies that grew incredibly 
fast and proceeded to IPO quickly, Web 2.0 companies are not able to follow the same 
pattern. While these companies have the same ability to grow exponentially, they do not 
share the ability to generate high revenue streams early on. Without a strong, sufficient 
revenue stream, the risk of IPO is too high. Companies instead rely on early acquisition by 
1.0 giants that are well established and already public to achieve a high return on investment 
(Caufield, 2007). In our case it is possible that a large tech transfer organization (e.g. UTEK) 
will acquire us, or one of the large event planners.  
  
 Year 3 valuation has been calculated at $5.3 million using an industry EBIT multiple 
of 6. While the multiple seems high relative to some industries, Web 2.0 companies can 
achieve a high value in a short time (Canaccord, 2008) and the estimate is considered to be 
conservative as revenues were kept below industry forecasts (as per benchmark 
organizations). Exit at Year 3 provides investors with an IRR of 26.5% (detailed financials 
provided in Appendices), but it is possibly that we would maintain the business into Year 5 
in order to achieve a higher return on investment. 
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 9:  CONCLUSION 
 
We are confident that Pharma 2.0 will be the first of its kind to meet the information and 
communication needs of  professionals in the pharmaceutical and biotechnology industry. As 
a free resource, it will be open to all clients as a tool to learn about the competitive 
environment and manage communication with future partners. The planned architecture of 
the site is intended to encourage network effects and make navigation straightforward and 
simple. 
 
 We will seek online advertising as a means to create a sustainable, positive revenue 
stream. To attract advertisers, we’ll need to have a user base of between 500 and 1000 users 
for this specialized product. Therefore, our sales and marketing strategy are of utmost 
importance in the first two years and will be where we focus our efforts.  
 
 To move forward in development of the web site, we anticipate a start-up cost of 
approximately $500,000. We would like to cover this initial cost through grant funding 
and/or friends and family investment. Within the following two years, we will require an 
influx of $1 million from either venture capital or angel investment, for which we will offer 
up to 30% of the firm. Our proforma financials indicate that we can be profitable by year 3 
and will provide our investors with a return on investment of nearly 27%. 
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 10:  APPENDICES 
 
 
Appendix 1 - Assumptions for Financial Model
Year 1 Year 2 Year 3 Worst Case Most Likely Best Case
Sales Growth N/A 250% 125% $0 $60,000 $150,000
Material Costs as a % of sales 2% 2% 2% $75,000 $120,000 $225,000
General and Admin as a % of sales 10% 10% 10% $75,000 $180,000 $375,000
Commission as a % of sales N/A 10% 10%
Marketing Exp as a % of sales 35% 15% 15%
Web Expense as a % of sales 14% 15% 15%
Admin Exp as a % of sales 7% 7% 7%
Interest Rates
Loan N/A N/A N/A
Debt Financing N/A N/A N/A
Tax Rate 15% 35% 35%
Capital Assets/ Depreciaiton
Opening Capital Assets $500,000
Capital Expenditure $300,000
Depreciation   20%
Assumptions Advertising* (note 2)
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 Appendix 2 - Value of the Firm and Return on Investment
Discount Rate 25.00%
VALUE OF FIRM Present
Cash Value
2010
2011
Terminal $5,334,000 $4,267,200
Value if Kept $4,267,200
Terminal Value Calculation
EBIT in year 2011 $889,000
EBIT Multiple 6
Terminal Value $5,334,000
Equity Funding Required $1,000,000
Inferred Percentage of Firm 23.4%
Percentage of Firm Offered 30.0%
IRR for Investors
Purchase/ Total Present
Sale Dividend Cash Value
2010 ($1,000,000) $0 ($1,000,000) ($1,000,000)
$0 $0 $0 $0
Terminal $1,600,200 $0 $1,600,200 $1,600,200
Investment Value 26.5% $600,200
Value of Firm and IRR
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 Appendix 3 - ProForma Balance Sheet
Starting 
Balance 2009 2010 2011
Assets
Current Assets
Cash and Equivalents $500,000 $23,800 $996,963 $577,850
Accounts Receivable $0 $9,000 $64,800 $162,000
Inventories $0 $0 $0 $0
Other $0 $0 $0 $0
Total Current Assets $500,000 $32,800 $1,061,763 $739,850
Long-Term Assets $0 $0 $0 $0
IT Hardware & Office Equipment $50,000 $150,000 $200,000
Intangible Assets (note 8) $50,000 $100,000
Total Long-Term Assets $0 $50,000 $200,000 $300,000
Total Assets $500,000 $82,800 $1,261,763 $1,039,850
Liabilities
Current Liabilities
Accounts Payable $0 $7,200 $81,000 $202,500
Taxes Payable $0 $0 $0 $0
Other $0 $0 $0 $0
Total Current Liabilities $0 $7,200 $81,000 $202,500
Long-Term Liabilities
Miscellaneous Loans $0 $0 $0 $0
Equity
Existing Shareholders' Equity $0 $75,600 $180,763 $837,350
New Preferred Equity $0 $0 $0 $0
New Common Equity $0 $0 $1,000,000 $0
Total Common Equity $0 $75,600 $1,180,763 $837,350
Retained Earnings $0 $0 $0 $0
Required Financing / Funding $500,000 $0 $0 $0
Total Liabilities & Equity $500,000 $82,800 $1,261,763 $1,039,850
Check 0 0 0 0
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 Appendix 4 - ProForma Income Statement
Income Statement 2009 2010 2011
Revenue* (notes 1&2) $180,000 $810,000 $2,025,000
Other Revenue $50,000 $150,000
$860,000 $2,175,000
Cost of Sales:
    Materials $3,600 $16,200 $40,500
    Direct Labor $100,000 $280,000 $480,000
    Commission $0 $50,000 $80,000
Total Direct Costs $103,600 $346,200 $600,500
Gross Profit $76,400 $513,800 $1,574,500
Indirect Costs:
Marketing Expense (note 3) $110,000 $121,500 $303,750
Market Intelligence (note 4) $100,000 $100,000 $150,000
Web Maintenance $50,000 $50,000 $50,000
Administration $12,600 $56,700 $141,750
Other Operating  (note 5) $10,000 $15,000 $15,000
Total Indirect Costs $282,600 $328,200 $645,500
EBITDA ($206,200) $185,600 $929,000
Depreciation of Fixed Assets $10,000 $30,000 $40,000
Amortization of Deferred Costs $0 $0 $0
EBIT ($216,200) $155,600 $889,000
Interest (note 6)
Term Loan $0 $0 $0
Other Loans $0 $0 $0
Total Interest $0 $0 $0
Operating Profit ($216,200) $155,600 $889,000
Other
Other Income $0 $0 $0
$0 $0 $0
Earnings Before Tax ($216,200) $155,600 $889,000
Tax (note 7) $0 $54,460 $311,150
Net Income ($216,200) $101,140 $577,850
Less Preferred Dividends $0 $0
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 Appendix 5 - ProForma Statement of Cash Flows
Starting 
Balance 2009 2010 2011
Cash Provided by(used in):
($216,200) $101,140 $577,850
($10,000) ($30,000) ($40,000)
$0 $0 $0
Changes in non cash balances:
Accounts Receivable $0 $10,114 $57,785
Accounts Payable $0 ($8,091) ($46,228)
Prepaid Expenses $0 $0 $0
Investments:
Purchase of Property and Equipment ($50,000) $0 ($100,000) ($200,000)
Investment in Web Site ($200,000) $0 $0 $0
Proceeds from sale of investments $0 $0 $0
Financing:
Paid-In capital from grant funding $500,000 $0 $0 $0
Issuance of Common stock $0 $1,000,000 $0
Increase (Decrease) in cash and cash equivalents ($250,000) ($226,200) $973,163 $349,407
Cash and Equivalents, beginning of year $500,000 $250,000 $23,800 $996,963
Cash and Equivalents, end of year $250,000 $23,800 $996,963 $1,346,370
Cash Flows
Depreciation and Amortization
Net Income for the year 
Operations:
Items not involving cash:
Stock-based compensation
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